Significant expansion of global commercial leadership team led by new CEO, Dale Levitzke, to address global demand for the Cyto-Mine Chroma platform.
Cambridge, UK, 14th November 2024: Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for functional profiling of single cells at scale, today announced a significant expansion of its global commercial presence. The Company has established a new direct sales and support channel for customers in North America and made several commercial leadership changes globally. These milestones reflect the ongoing strategic focus on operational scale-up to address demand for the Company’s Cyto-Mine® platform and provide local specialized support.
Dr. Jay Manikandan, VP of Commercial, APAC, Sphere Fluidics
Jay Gerlach, VP of Global Marketing, Sphere Fluidics
Dr. Erroll Rueckert, North America Commercial Director, Sphere Fluidics
As North America Commercial Director, Dr. Erroll Rueckert has joined to lead a new and rapidly expanding sales team for the American market. Central to this role is building a new direct sales channel in this key region, streamlining customer access to its portfolio of products, including the recently announced Cyto-Mine Chroma platform. Erroll has strong commercial and technical expertise in single cell analysis, spatial biology, and genomics. Prior to Sphere, Erroll held roles of increasing responsibility at NanoString and Lightcast Discovery.
Dr. Graeme Daniels, VP of Commercial (EMEA), oversees the Company’s commercial team in EMEA, which is continuing to significantly expand in response to a growing European customer base. An important part of the expansion will be to pivot from distributed to direct sales in Germany, France, Benelux, and Nordic countries. Graeme brings extensive commercial leadership experience honed at companies providing products and services to BioPharma companies including: IsoPlexis, Horizon Discovery, and Revvity (formerly PerkinElmer).
Dr. Jay Manikandan has been appointed as VP of Commercial (APAC). Based in Singapore, he is a proven commercial leader and will drive the Company’s commercial growth in the region, including managing a network of industry-leading distributors. Jay’s experience managing sales throughout APAC for companies such as 10x Genomics, NanoString, and Bruker Spatial Biology sets him up for success in building a strong commercial channel for Sphere in this region.
These key regional teams, combined with a strengthened global marketing team led by the newly-appointed US-based Jay Gerlach as VP of Global Marketing, will enable Sphere to bring the benefits of the Cyto-Mine Chroma platform to customers globally. Prior to Sphere, Jay held product management and marketing positions of increasing responsibility at a number of innovative companies including PATH, NanoString, and Purigen.
Dale Levitzke, CEO, Sphere Fluidics, said: “We are strategically-focused on scaling operations globally, which is reinforced by the establishment of our first comprehensive direct sales and support channel in the US. We are recruiting high-performing, experienced sales professionals and implementing a proven process for driving the right behaviors as we scale globally. These developments are essential for ensuring we proactively respond to market demand, enhance the customer experience, drive innovation, and grow the company.”
Jay Gerlach, VP of Global Marketing, Sphere Fluidics, commented: “This expansion marks a major step forward for the Company in maximizing customer engagement and global market presence. There is a lot of untapped demand for Cyto-Mine and we are scaling to address the opportunity. By investing in localized teams and leadership in crucial regions like North America, Europe and Asia Pacific, we can provide the best possible solutions to transform researchers’ single cell discovery and development workflows globally.”
For further information please contact:
Dr Claire Cox
Sphere Fluidics Ltd.
Tel: +44 (0)7365 209 441
Email: claire.cox@spherefluidics.com
Zyme Communications
Lily Jeffery
Tel: +44 (0)7891 477 378
Email: lily.jeffery@zymecommunications.com
About Sphere Fluidics
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems to enable researchers to find, analyze and isolate the most valuable cells, with ease and speed.
Sphere Fluidics’ proprietary picodroplet microfluidic platforms are designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a picodroplet, while maintaining viability. Harnessing this technology, the Company’s range of novel microfluidic tools facilitate leading-edge research and accelerate biotherapeutic discovery and development, cell therapy, and synthetic biology workflows, streamlining the journey of discovery in labs, globally.
Sphere Fluidics is based at Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors.
For further information contact:
